Harvest Technologies to Present at Medtech Insight and Windhover Information's ``In3 Europe'' Investor Conference in Brussels, Belgium, Sept. 18-20, 2006.

PLYMOUTH, Mass. -- Harvest Technologies Corp.:

--Company has developed world's first product (BMAC(TM) System) that makes possible the use of cellular compositions from autologous bone marrow, including adult stem cells, derived from the patient, at the point-of-care, in just 15 minutes

--BMAC now being used in Europe to treat orthopedic, vascular and cardiovascular diseases

Harvest Technologies Corp. (www.harvesttech.com) announced today that its President, Gary D. Tureski, will present at Medtech Insight and Windhover Information's "In3 Europe" investor conference, Sept. 18-20, 2006, at the Crowne Plaza City Center, Brussels, Belgium. On February 6, 2006, Harvest Technologies received FDA clearance to concentrate the cellular components from bone marrow via its breakthrough BMAC(TM) (Bone Marrow Aspirate Concentrate) System. The BMAC System is currently being used in Europe to treat vascular, orthopedic and cardiovascular diseases. It is the world's first product that makes possible the use of a clinically effective quantity of cellular compositions from a small aspirate of autologous bone marrow, including a large quantity of adult stem cells, derived from a patient at the point-of-care, in just 15 minutes.

It is well established in the scientific literature that a concentrate of autologous adult stem cells from bone marrow is safe and clinically effective in achieving tissue regeneration in cardiovascular and vascular diseases. A concentrate of these cells contains "not only stem cells and precursor cells as a source of regeneration tissue, but also accessory cells that support angiogenesis and vasculogenesis by producing several growth factors and cytokines" (Saigawa, et al.; Circulation Journal; vol. 68, December 2004; 68:1189-1193). Until now, it has been difficult to process and concentrate a clinically significant dose of adult stem cells from a patient's bone marrow at the point-of-care.

"Adult stem cells derived from autologous bone marrow have been documented to be clinically effective and extremely safe -- but until now, the procurement of these cells has been a laborious and tedious process," said Tureski. "Our novel technology makes it possible to easily and quickly process and concentrate cellular compositions from bone marrow, including a large quantity of adult stem cells, safely and rapidly to aid in point-of-care treatment of difficult-to-treat diseases, as demonstrated by the company's clinical experience in the EC."

Harvest's BMAC System is a breakthrough because it can process and concentrate cellular components, including the adult stem cells from autologous bone marrow at the point-of-care in just 15 minutes. The concentrate produced by the BMAC System has been documented to be superior to concentrations obtained by using other, laborious laboratory methods used in successful clinical studies -- while being significantly easier to implement and requiring one-third-less bone marrow aspirate from the patient. There are 20 published clinical studies involving 1,483 patients at 36 sites around the world demonstrating that this approach (adult stem cells derived from autologous bone marrow) enables clinicians to offer new therapies for a variety of serious diseases.

An IDE/PMA multicenter clinical study using Harvest's BMAC System will be underway this fall targeting patients with Critical Limb Ischemia (CLI), which is the later stage of Peripheral Arterial Disease (PAD) -- clogged arteries, particularly in the lower legs. Patients with CLI are at extreme risk for amputation. Approximately 500,000 people worldwide suffer from CLI, and about 160,000 amputations are performed each year in the U.S. as a result of this condition (source: The Sage Group). A recent pilot study conducted in Berlin, using the BMAC System to produce adult stem cell therapy, showed a 60 percent reduction in amputation for patients with severe Critical Limb Ischemia. An additional randomized prospective clinical study is scheduled to commence this fall as well in the EC.

A division of Windhover Information Inc., Medtech Insight is the leading provider of business information and market intelligence for the medical technology marketplace. "In3 Europe" is Medtech Insight's 22nd investment and partnering event to date. To register to attend or for more information, please call Kristy Grimes at 480-985-9512 or 888-202-5939 toll-free in the U.S., e-mail [e-mail], or visit www.medtechinsight.com.